Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd
SZSE:002864.SZ
36.39 (CNY) • At close October 26, 2023
Overview | Financials
Numbers are in millions (except for per share data and ratios) CNY.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 973.864 | 980.828 | 974.293 | 887.485 | 670.313 | 610.637 | 489.448 | 376.792 | 305.426 | 256.097 | 245.695 | 226.614 |
| Cost of Revenue
| 381.516 | 412.746 | 408.009 | 370.272 | 252.756 | 186.259 | 141.213 | 115.934 | 113.009 | 90.493 | 72.307 | 69.853 |
| Gross Profit
| 592.348 | 568.082 | 566.284 | 517.213 | 417.557 | 424.378 | 348.235 | 260.857 | 192.416 | 165.604 | 173.388 | 156.762 |
| Gross Profit Ratio
| 0.608 | 0.579 | 0.581 | 0.583 | 0.623 | 0.695 | 0.711 | 0.692 | 0.63 | 0.647 | 0.706 | 0.692 |
| Reseach & Development Expenses
| 37.538 | 20.256 | 18.234 | 14.026 | 12.971 | 13.078 | 8.291 | 7.229 | 2.943 | 2.428 | 2.18 | 2.306 |
| General & Administrative Expenses
| 26.404 | 19.098 | 16.321 | 16.629 | 14.499 | 13.443 | 15.629 | 9.288 | 6.604 | 7.39 | 8.697 | 21.566 |
| Selling & Marketing Expenses
| 337.677 | 362.189 | 362.742 | 333.196 | 262.834 | 281.365 | 237.888 | 169.678 | 119.714 | 93.022 | 103.38 | 97.056 |
| SG&A
| 364.08 | 414.844 | 379.063 | 349.826 | 277.333 | 294.808 | 253.518 | 178.967 | 126.318 | 100.412 | 112.076 | 118.623 |
| Other Expenses
| 52.363 | -0.738 | 44.263 | 43.293 | 32.648 | 35.285 | 9.153 | -1.134 | 2.288 | 2.104 | 4.649 | 2.738 |
| Operating Expenses
| 453.981 | 433.223 | 441.559 | 407.145 | 322.951 | 343.171 | 291.549 | 211.116 | 147.622 | 116.423 | 125.932 | 121.465 |
| Operating Income
| 138.367 | 134.859 | 123.022 | 112.525 | 94.978 | 86.355 | 66.166 | 50.122 | 44.251 | 48.293 | 43.447 | 34.284 |
| Operating Income Ratio
| 0.142 | 0.137 | 0.126 | 0.127 | 0.142 | 0.141 | 0.135 | 0.133 | 0.145 | 0.189 | 0.177 | 0.151 |
| Total Other Income Expenses Net
| -1.415 | -5.611 | -3.842 | -3.496 | -0.481 | -2.804 | 9.153 | -0.104 | 1.783 | 1.239 | 2.06 | 2.738 |
| Income Before Tax
| 136.952 | 129.249 | 119.18 | 109.029 | 94.497 | 83.551 | 75.319 | 50.018 | 46.181 | 49.533 | 45.507 | 37.022 |
| Income Before Tax Ratio
| 0.141 | 0.132 | 0.122 | 0.123 | 0.141 | 0.137 | 0.154 | 0.133 | 0.151 | 0.193 | 0.185 | 0.163 |
| Income Tax Expense
| 17.027 | 17.704 | 16.033 | 14.473 | 13.405 | 11.772 | 10.637 | 6.299 | 6.601 | 6.835 | 6.61 | 5.149 |
| Net Income
| 120.272 | 110.432 | 101.164 | 93.17 | 79.115 | 71.779 | 64.682 | 43.719 | 39.528 | 42.638 | 40.072 | 32.894 |
| Net Income Ratio
| 0.123 | 0.113 | 0.104 | 0.105 | 0.118 | 0.118 | 0.132 | 0.116 | 0.129 | 0.166 | 0.163 | 0.145 |
| EPS
| 1.15 | 1.15 | 1.18 | 1.09 | 0.92 | 0.83 | 0.75 | 0.65 | 0.61 | 0.66 | 0.62 | 0.51 |
| EPS Diluted
| 1.15 | 1.13 | 1.17 | 1.09 | 0.92 | 0.83 | 0.75 | 0.65 | 0.61 | 0.66 | 0.62 | 0.51 |
| EBITDA
| 171.479 | 166.695 | 150.885 | 129.374 | 112.026 | 96.865 | 87.218 | 58.847 | 52.499 | 55.121 | 51.425 | 35.297 |
| EBITDA Ratio
| 0.176 | 0.17 | 0.155 | 0.146 | 0.167 | 0.159 | 0.178 | 0.156 | 0.172 | 0.215 | 0.209 | 0.156 |